08:00 AM EST - BioVaxys Technology Corp. : Announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candidate, and CoviDTH, its immunodiagnostic product. Both are headed for clinical trials, with BioVaxys having begun preparing an IND submission to the US Food and Drug Administration ("FDA") for a combined Phase I/II clinical study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.38.
